novartis

Phase I Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

Description:

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [177Lu]Lu-NNS309 and the safety and imaging properties of [68Ga]Ga-NNS309 in patients aged ≥ 18 years with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), HR+/HER2- ductal and lobular breast cancer (BC), triple negative breast cancer (TNBC) and colorectal cancer (CRC).

Lutetium (177Lu) oxodotreotide

Isotope(s):
Target(s):
  • SSTR2
Ligand: Peptides
Linker: Dotatate

Patient Education


Patient Education Not Yet Provided

Publications


Publications Not Yet Provided

Locations


Not yet provided.

XCancer

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468